PMID: 11910258Mar 23, 2002Paper

Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia

Journal of Clinical Psychopharmacology
Maurizio FavaJill S Gonzales

Abstract

This study assessed whether fluoxetine, sertraline, and paroxetine differ in efficacy and tolerability in depressed patients and the impact of baseline insomnia on outcomes. Patients (N = 284) with DSM-IV major depressive disorder were randomly assigned in a double-blind fashion to fluoxetine, paroxetine, or sertraline for 10 to 16 weeks of treatment. Using the Hamilton Rating Scale for Depression (HAM-D) sleep disturbance factor score, patients were categorized into low (<4) or high (>or=4) baseline insomnia subgroups. Changes in depression and insomnia were assessed. Safety assessments included treatment-emergent adverse events (AEs), reasons for discontinuation, and AEs leading to discontinuation. In addition, AEs were evaluated within insomnia subgroups to determine emergence of activation or sedation. Depression improvement, assessed with the HAM-D-17 total score, was similar among treatments in all patients (p = 0.365) and the high (p = 0.853) and low insomnia (p = 0.415) subgroups. Insomnia improvement, assessed with the HAM-D sleep disturbance factor score, was similar among treatments in all patients (p = 0.868) and in the high (p = 0.852) and low insomnia (p = 0.982) subgroups. Analyses revealed no significant differe...Continue Reading

References

Jan 1, 1993·International Clinical Psychopharmacology·E AgugliaF Bolino
Jun 1, 1996·Journal of Clinical Psychopharmacology·E Richelson
Jul 14, 1999·Journal of Affective Disorders·G ChouinardM C O'Neill
Oct 21, 1999·International Clinical Psychopharmacology·M F FlamentZ Ying
Nov 26, 1999·European Psychiatry : the Journal of the Association of European Psychiatrists·D SechterP Boyer
Sep 12, 2000·The Journal of Clinical Psychiatry·P A NewhouseC M Clary

❮ Previous
Next ❯

Citations

Nov 30, 2012·CNS Drugs·Andrea FagioliniSiegfried Kasper
Sep 27, 2003·Clinical Therapeutics·Prakash S Masand
Apr 11, 2008·International Journal of Technology Assessment in Health Care·Gerald Gartlehner, Charity G Moore
Apr 25, 2006·Journal of Palliative Medicine·Elizabeth A Kvale, John L Shuster
Dec 1, 2005·International Clinical Psychopharmacology·Kunitoshi KamijimaToshimitsu Hamasaki
Mar 1, 2009·International Clinical Psychopharmacology·David V Sheehan, Kunitoshi Kamijima
Jul 25, 2006·Primary Care Companion to the Journal of Clinical Psychiatry
Dec 18, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Ursula ReichenpfaderBradley N Gaynes
Mar 6, 2004·Bipolar Disorders·Benjamin J D H Chun, David L Dunner
Oct 12, 2013·Depression and Anxiety·Maurizio FavaMichael E Thase
Oct 24, 2003·Biological Psychiatry·Roy H PerlisMaurizio Fava
Oct 24, 2013·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Ying WangQianping Wei
Sep 1, 2004·Expert Opinion on Drug Safety·Joachim F Wernicke
Apr 10, 2015·BMC Medicine·Gerwyn MorrisMichael Maes
Dec 17, 2014·Journal of Affective Disorders·Sharon C SungUNKNOWN COMED Study Team
Mar 20, 2013·Journal of Affective Disorders·Ramakrishnan VenkatasubramanianRavi Shankar Pandey
Oct 13, 2007·Journal of Attention Disorders·Jamie G WoodKelly D Heiskell
Oct 22, 2013·The American Journal of Hospice & Palliative Care·Raghava R Induru, Declan Walsh
Apr 29, 2006·Journal of Psychopharmacology·Maurizio Fava
Oct 18, 2005·Human Psychopharmacology·Andrew G Mayers, David S Baldwin
Apr 4, 2014·The Cochrane Database of Systematic Reviews·Marianna PurgatoCorrado Barbui
Jan 26, 2005·Menopause : the Journal of the North American Menopause Society·Eila Suvanto-LuukkonenJuha S Tapanainen
Apr 16, 2010·The Cochrane Database of Systematic Reviews·Andrea CiprianiCorrado Barbui
May 16, 2018·The Cochrane Database of Systematic Reviews·Hazel EverittSue Wilson
Dec 15, 2006·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Yoshimitsu HaradaTakayuki Imaeda
Mar 10, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Scott PattenCorrado Barbui
Jan 2, 2007·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Maurizio FavaKathy Shores-Wilson
Feb 5, 2010·Journal of Midwifery & Women's Health·Barbara HackleyShared Sreenivasan
Sep 2, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gerald GartlehnerKathleen N Lohr
Dec 20, 2013·The Cochrane Database of Systematic Reviews·Laura R MagniCorrado Barbui

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.